These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16334989)

  • 1. Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.
    Tachedjian G; Mijch A
    Sex Health; 2004; 1(2):81-9. PubMed ID: 16334989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
    Harrigan PR; Hertogs K; Verbiest W; Larder B; Yip B; Brumme ZL; Alexander C; Tilley J; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):395-402. PubMed ID: 14640386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
    AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NNRTI hypersusceptibility.
    Delgado J; Shulman N
    AIDS Read; 2005 Jan; 15(1):28-30, 32-4. PubMed ID: 15685732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of antiretroviral-drug-resistant HIV: is there any possible clinical advantage?
    Zaccarelli M; Tozzi V; Perno CF; Antinori A
    Curr HIV Res; 2004 Jul; 2(3):283-92. PubMed ID: 15279592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
    AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.
    Hofstra LM; Sauvageot N; Albert J; Alexiev I; Garcia F; Struck D; Van de Vijver DAMC; Åsjö B; Beshkov D; Coughlan S; Descamps D; Griskevicius A; Hamouda O; Horban A; Van Kasteren M; Kolupajeva T; Kostrikis LG; Liitsola K; Linka M; Mor O; Nielsen C; Otelea D; Paraskevis D; Paredes R; Poljak M; Puchhammer-Stöckl E; Sönnerborg A; Staneková D; Stanojevic M; Van Laethem K; Zazzi M; Zidovec Lepej S; Boucher CAB; Schmit JC; Wensing AMJ; ; Puchhammer-Stockl E; Sarcletti M; Schmied B; Geit M; Balluch G; Vandamme AM; Vercauteren J; Derdelinckx I; Sasse A; Bogaert M; Ceunen H; De Roo A; De Wit S; Echahidi F; Fransen K; Goffard JC; Goubau P; Goudeseune E; Yombi JC; Lacor P; Liesnard C; Moutschen M; Pierard D; Rens R; Schrooten Y; Vaira D; Vandekerckhove LPR; Van den Heuvel A; Van Der Gucht B; Van Ranst M; Van Wijngaerden E; Vandercam B; Vekemans M; Verhofstede C; Clumeck N; Van Laethem K; Beshkov D; Alexiev I; Lepej SZ; Begovac J; Kostrikis L; Demetriades I; Kousiappa I; Demetriou V; Hezka J; Linka M; Maly M; Machala L; Nielsen C; Jørgensen LB; Gerstoft J; Mathiesen L; Pedersen C; Nielsen H; Laursen A; Kvinesdal B; Liitsola K; Ristola M; Suni J; Sutinen J; Descamps D; Assoumou L; Castor G; Grude M; Flandre P; Storto A; Hamouda O; Kücherer C; Berg T; Braun P; Poggensee G; Däumer M; Eberle J; Heiken H; Kaiser R; Knechten H; Korn K; Müller H; Neifer S; Schmidt B; Walter H; Gunsenheimer-Bartmeyer B; Harrer T; Paraskevis D; Hatzakis A; Zavitsanou A; Vassilakis A; Lazanas M; Chini M; Lioni A; Sakka V; Kourkounti S; Paparizos V; Antoniadou A; Papadopoulos A; Poulakou G; Katsarolis I; Protopapas K; Chryssos G; Drimis S; Gargalianos P; Xylomenos G; Lourida G; Psichogiou M; Daikos GL; Sipsas NV; Kontos A; Gamaletsou MN; Koratzanis G; Sambatakou H; Mariolis H; Skoutelis A; Papastamopoulos V; Georgiou O; Panagopoulos P; Maltezos E; Coughlan S; De Gascun C; Byrne C; Duffy M; Bergin C; Reidy D; Farrell G; Lambert J; O'Connor E; Rochford A; Low J; Coakely P; O'Dea S; Hall W; Mor O; Levi I; Chemtob D; Grossman Z; Zazzi M; de Luca A; Balotta C; Riva C; Mussini C; Caramma I; Capetti A; Colombo MC; Rossi C; Prati F; Tramuto F; Vitale F; Ciccozzi M; Angarano G; Rezza G; Kolupajeva T; Vasins O; Griskevicius A; Lipnickiene V; Schmit JC; Struck D; Sauvageot N; Hemmer R; Arendt V; Michaux C; Staub T; Sequin-Devaux C; Wensing AMJ; Boucher CAB; van de Vijver DAMC; van Kessel A; van Bentum PHM; Brinkman K; Connell BJ; van der Ende ME; Hoepelman IM; van Kasteren M; Kuipers M; Langebeek N; Richter C; Santegoets RMWJ; Schrijnders-Gudde L; Schuurman R; van de Ven BJM; Åsjö B; Kran AB; Ormaasen V; Aavitsland P; Horban A; Stanczak JJ; Stanczak GP; Firlag-Burkacka E; Wiercinska-Drapalo A; Jablonowska E; Maolepsza E; Leszczyszyn-Pynka M; Szata W; Camacho R; Palma C; Borges F; Paixão T; Duque V; Araújo F; Otelea D; Paraschiv S; Tudor AM; Cernat R; Chiriac C; Dumitrescu F; Prisecariu LJ; Stanojevic M; Jevtovic D; Salemovic D; Stanekova D; Habekova M; Chabadová Z; Drobkova T; Bukovinova P; Shunnar A; Truska P; Poljak M; Lunar M; Babic D; Tomazic J; Vidmar L; Vovko T; Karner P; Garcia F; Paredes R; Monge S; Moreno S; Del Amo J; Asensi V; Sirvent JL; de Mendoza C; Delgado R; Gutiérrez F; Berenguer J; Garcia-Bujalance S; Stella N; de Los Santos I; Blanco JR; Dalmau D; Rivero M; Segura F; Elías MJP; Alvarez M; Chueca N; Rodríguez-Martín C; Vidal C; Palomares JC; Viciana I; Viciana P; Cordoba J; Aguilera A; Domingo P; Galindo MJ; Miralles C; Del Pozo MA; Ribera E; Iribarren JA; Ruiz L; de la Torre J; Vidal F; Clotet B; Albert J; Heidarian A; Aperia-Peipke K; Axelsson M; Mild M; Karlsson A; Sönnerborg A; Thalme A; Navér L; Bratt G; Karlsson A; Blaxhult A; Gisslén M; Svennerholm B; Bergbrant I; Björkman P; Säll C; Mellgren Å; Lindholm A; Kuylenstierna N; Montelius R; Azimi F; Johansson B; Carlsson M; Johansson E; Ljungberg B; Ekvall H; Strand A; Mäkitalo S; Öberg S; Holmblad P; Höfer M; Holmberg H; Josefson P; Ryding U
    Clin Infect Dis; 2016 Mar; 62(5):655-663. PubMed ID: 26620652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
    Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
    J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.